Compare EC & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EC | RVMD |
|---|---|---|
| Founded | 1948 | 2014 |
| Country | Colombia | United States |
| Employees | N/A | 883 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 30.1B |
| IPO Year | 2008 | N/A |
| Metric | EC | RVMD |
|---|---|---|
| Price | $13.83 | $152.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $140.84 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $533.02 |
| P/E Ratio | $170.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.27 | $34.00 |
| 52 Week High | $15.62 | $155.70 |
| Indicator | EC | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 61.99 |
| Support Level | $12.75 | $93.39 |
| Resistance Level | $14.51 | $152.38 |
| Average True Range (ATR) | 0.51 | 5.45 |
| MACD | 0.08 | -0.69 |
| Stochastic Oscillator | 68.93 | 72.76 |
Ecopetrol SA is engaged in commercial and industrial activities related to the exploration, exploitation, refining, transportation, storage, distribution, and marketing of hydrocarbons, their derivatives, and products, as well as the electric power transmission services, design, development, construction, operation, and maintenance of road and energy infrastructure projects and the provision of information technology and telecommunications services. The operations of the company are performed through four business segments: Exploration and Production, Transport and Logistics, Refining and Petrochemical, and Electric Power Transmission and Toll Roads Concessions. The majority of the company's revenue is generated from the Exploration and Production segment.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.